In a report released today, Robert Burns from H.C. Wainwright reiterated a Hold rating on BioNTech SE (BNTX). The company’s shares closed last Friday at $104.07, close to its 52-week high of $115.00.
According to TipRanks.com, Burns is a 5-star analyst with an average return of 48.6% and a 76.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.
BioNTech SE has an analyst consensus of Moderate Buy, with a price target consensus of $102.43, which is a 2.4% upside from current levels. In a report issued on November 10, J.P. Morgan also maintained a Hold rating on the stock with a $90.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $115.00 and a one-year low of $20.38. Currently, BioNTech SE has an average volume of 2.98M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany.
Read More on BNTX:
